Infectious Diseases Partnering Terms and Agreements, 2014 to 2020

DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Infectious Diseases Partnering Deals Collection 2014-2020: Deal Trends, Players and Financials" report has been added to's offering.

This report provides the full collection of Infectious Diseases disease deals signed between the world's leading pharmaceutical and biotechnology companies since 2014.

    --  Trends in Infectious Diseases dealmaking in the biopharma industry since
    --  Analysis of Infectious Diseases deal structure
    --  Access to headline, upfront, milestone and royalty data
    --  Access to hundreds of Infectious Diseases deal contract documents
    --  Comprehensive access to over 1500 Infectious Diseases deal records
    --  The leading Infectious Diseases deals by value since 2014
    --  Most active Infectious Diseases dealmakers since 2014

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.

The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Infectious Diseases dealmaking trends.

    --  Chapter 1 provides an introduction to the report.
    --  Chapter 2 provides an overview of the trends in Infectious Diseases
        dealmaking since 2014 covering trends by year, deal type, stage of
        development, technology type and therapeutic indication.
    --  Chapter 3 includes an analysis of financial deal terms covering headline
        value, upfront payment, milestone payments and royalty rates.
    --  Chapter 4 provides a review of the leading Infectious Diseases deals
        since 2014. Deals are listed by headline value. The - Chapter includes
        the top 25 most active Infectious Diseases dealmakers, together with a
        full listing of deals to which they are a party. Where the deal has an
        agreement contract published at the SEC a link provides online access to
        the contract.
    --  Chapter 5 provides comprehensive access to Infectious Diseases deals
        since 2014 where a deal contract is available, providing the user with
        direct access to contracts as filed with the SEC regulatory authorities.
        Each deal title links via Weblink to an online version of the deal
        record contract document, providing easy access to each contract
        document on demand.
    --  Chapter 6 provides a comprehensive directory of all Infectious Diseases
        partnering deals by specific Infectious Diseases target announced since
        2014. The Chapter is organized by specific Infectious Diseases
        therapeutic target. Each deal title links via Weblink to an online
        version of the deal record and where available, the contract document,
        providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Diseases partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Diseases technologies and products.

Analyzing actual contract agreements allows assessment of the following:

    --  What are the precise rights granted or optioned?
    --  What is actually granted by the agreement to the partner company?
    --  What exclusivity is granted?
    --  What is the payment structure for the deal?
    --  How are the sales and payments audited?
    --  What is the deal term?
    --  How are the key terms of the agreement defined?
    --  How are IPRs handled and owned?
    --  Who is responsible for commercialization?
    --  Who is responsible for development, supply, and manufacture?
    --  How is confidentiality and publication managed?
    --  How are disputes to be resolved?
    --  Under what conditions can the deal be terminated?
    --  What happens when there is a change of ownership?
    --  What sublicensing and subcontracting provisions have been agreed?
    --  Which boilerplate clauses does the company insist upon?
    --  Which boilerplate clauses appear to differ from partner to partner or
        deal type to deal type?
    --  Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

    --  2A
    --  3M
    --  3SBio
    --  4SC Discovery
    --  36 Strategies General Trading
    --  A*STAR Agency for Science
    --  Technology and Research
    --  A*STAR Institute of Microelectronics (IME)
    --  A*STAR Singapore Immunology Network
    --  A*STAR' Institute of Molecular and Cell Biology
    --  Aarhus University Hospital
    --  AB Analitica
    --  Abbott Laboratories
    --  Abbvie
    --  AbCellera
    --  Abeome
    --  ABIVAX
    --  Ablexis
    --  Academic Medical Center
    --  Academy of Military Medical Sciences (China)
    --  Accelerate Diagnostics
    --  Access BIO
    --  Achaogen
    --  Achillion Pharmaceuticals
    --  Actavis (name changed to Allergan)
    --  Actelion
    --  Acumen Pharmaceuticals
    --  Acurx Pharmaceuticals
    --  Adaptive Phage Therapeutics
    --  Adimab
    --  ADT Altona Diagnostic Technologies
    --  Advanced Accelerator Applications
    --  Advanced Biological Laboratories
    --  Advanced BioNutrition
    --  Advanced BioScience Laboratories
    --  Aelix Therapeutics
    --  Aeras
    --  Aethlon Medical
    --  Affinium Pharmaceuticals
    --  Affinivax
    --  Agenus Bio
    --  Aglon
    --  Agricultural Materials Company
    --  Agricultural Research Service
    --  AiCuris
    --  AIDS Clinical Trials Group
    --  AIDS Foundation of Chicago
    --  AIMM Therapeutics
    --  Aitbiotech
    --  AIT Therapeutics
    --  Akers Biosciences
    --  Akonni Biosystems
    --  Akorn
    --  Alamo Pharma Services
    --  Alaska Department of Health and Social Services
    --  Albert Einstein College of Medicine
    --  Aldevron
    --  Alere
    --  Alibaba Health
    --  Allergan
    --  Alnylam Pharmaceuticals
    --  Alphamab
    --  Alpha Tech Pet
    --  Altan Pharma
    --  Alverno Clinical Laboratories
    --  Alvogen
    --  Al Zahrawi Medical Supplies
    --  Amarex Clinical Research
    --  American Foundation for AIDS Research (amfAR)
    --  American Gene Technologies
    --  American Type Culture Collection (ATCC)
    --  Amerigen Pharmaceuticals
    --  Amgen
    --  Amneal Pharmaceuticals
    --  AmpliPhi Biosciences
    --  Amplyx Pharmaceuticals
    --  AMP Therapeutics
    --  AMR
    --  Anacor Pharmaceuticals
    --  Anatara Lifesciences
    --  Angelini Pharma
    --  AnGes MG
    --  ANI Pharmaceuticals
    --  Ansell
    --  Antengene
    --  Antigen Discovery
    --  Antitope
    --  AOP Orphan Pharmaceuticals
    --  Aperiomics
    --  Aphios
    --  ApolloBio
    --  Appili Therapeutics
    --  Applied BioCode
    --  Aptevo Therapeutics
    --  Aptimmune Biologics
    --  Aptuit
    --  Aqua Pharmaceuticals
    --  Aradigm
    --  Aralez Pharmaceuticals
    --  Arbutus
    --  ArcDia
    --  Arcturus Therapeutics
    --  Ares Genetics
    --  Ares Life Sciences
    --  Argos Therapeutics
    --  Aridis Pharmaceuticals
    --  Arisan Therapeutics
    --  Ark Animal Health
    --  Ark Biosciences
    --  Arno Therapeutics
    --  Arrevus
    --  Arrowhead Pharmaceuticals
    --  Arrow Pharmaceuticals
    --  Arsanis Biosciences
    --  Artes Biotechnology
    --  ARUP Laboratories
    --  Asclepia Outsourcing Solutions
    --  Ascletis
    --  Aseptix
    --  Asklepios Biopharmaceutical
    --  Aspen Holding
    --  Astellas Pharma
    --  Aston University
    --  Astra Formedic
    --  AstraZeneca
    --  Atara Biotherapeutics
    --  Atlangram
    --  Atlas Genetics
    --  Atomo Diagnostics
    --  Atomwise
    --  Atox Bio
    --  Aurobindo Pharma
    --  Auspherix
    --  Australian Research Council
    --  Autobio Diagnostics
    --  AUT Roche Diagnostics Laboratory
    --  AUT University
    --  Avanzcare
    --  Aviragen Therapeutics
    --  Axela
    --  Aytu BioScience
    --  AzurRx BioPharma
    --  Banco de Sangre de Servicios Mutuos
    --  Baruch S Blumberg Institute
    --  BASF
    --  Basilea Pharmaceutica
    --  Batavia Biosciences
    --  and many, many more!

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets